BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alexander M, Burbury K. A systematic review of biomarkers for the prediction of thromboembolism in lung cancer - Results, practical issues and proposed strategies for future risk prediction models. Thromb Res 2016;148:63-9. [PMID: 27815968 DOI: 10.1016/j.thromres.2016.10.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tawil N, Spinelli C, Bassawon R, Rak J. Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations. Thromb Res 2020;191 Suppl 1:S99-S105. [PMID: 32736787 DOI: 10.1016/S0049-3848(20)30405-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Georgakopoulos CD, Makri OE, Pallikari A, Kagkelaris K, Plotas P, Grammenou V, Emmanuil A. Effect of intravitreal injection of aflibercept on blood coagulation parameters in patients with age-related macular degeneration. Ther Adv Ophthalmol 2020;12:2515841420903929. [PMID: 32095777 DOI: 10.1177/2515841420903929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Yan AR, Samarawickrema I, Naunton M, Peterson GM, Yip D, De Rosa S, Mortazavi R. Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer. Healthcare (Basel) 2021;9:778. [PMID: 34205695 DOI: 10.3390/healthcare9060778] [Reference Citation Analysis]
4 Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130:1499-1506. [PMID: 28807983 DOI: 10.1182/blood-2017-03-743211] [Cited by in Crossref: 120] [Cited by in F6Publishing: 111] [Article Influence: 24.0] [Reference Citation Analysis]
5 Castellón Rubio VE, Segura PP, Muñoz A, Farré AL, Ruiz LC, Lorente JA. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score. Thromb Res 2020;196:349-54. [PMID: 32977135 DOI: 10.1016/j.thromres.2020.09.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sussman TA, Abazeed ME, McCrae KR, Khorana AA. RNA expression and risk of venous thromboembolism in lung cancer. Res Pract Thromb Haemost 2020;4:117-23. [PMID: 31989093 DOI: 10.1002/rth2.12284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Ferroni P, Zanzotto FM, Scarpato N, Riondino S, Guadagni F, Roselli M. Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology. Dis Markers. 2017;2017:8781379. [PMID: 29104344 DOI: 10.1155/2017/8781379] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
8 Shah S, Karathanasi A, Revythis A, Ioannidou E, Boussios S. Cancer-Associated Thrombosis: A New Light on an Old Story. Diseases 2021;9:34. [PMID: 34064390 DOI: 10.3390/diseases9020034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Papadopoulos V, Tsapakidis K, Markou A, Kokkalis A, Aidarinis C, Kotsakis A. New prophylaxis strategies to reduce the risk of thromboembolism in cancer. Expert Rev Anticancer Ther 2021. [PMID: 34139938 DOI: 10.1080/14737140.2021.1941889] [Reference Citation Analysis]
10 Riondino S, Ferroni P, Zanzotto FM, Roselli M, Guadagni F. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers (Basel) 2019;11:E95. [PMID: 30650562 DOI: 10.3390/cancers11010095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
11 Li LJ, Chen DF, Wu GF, Guan WJ, Zhu Z, Liu YQ, Gao GY, Qin YY, Zhong NS. Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma. J Thorac Dis 2018;10:5010-22. [PMID: 30233875 DOI: 10.21037/jtd.2018.07.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
12 Petrelli F, Cabiddu M, Borgonovo K, Parati MC, Ghilardi M, Perego G, Luciani A. Osimertinib-related venous thromboembolism in non small lung cancer. Thromb Res 2021;210:63-6. [PMID: 35007938 DOI: 10.1016/j.thromres.2021.12.019] [Reference Citation Analysis]
13 Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. Oncologist 2018;23:1372-81. [PMID: 30104289 DOI: 10.1634/theoncologist.2017-0530] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
14 Brenner B, Hull R, Arya R, Beyer-Westendorf J, Douketis J, Elalamy I, Imberti D, Zhai Z. Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. Thromb J 2019;17:6. [PMID: 31011294 DOI: 10.1186/s12959-019-0196-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]